0
0
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight - Eli Lilly
1/8/26 at 7:02pm
Organization
Lilly.com
52 words
0
Comments
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
You are the first to view
https://investor.lilly.com/news-releases/news-release-details/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together
Create an account or login to join the discussion